Cargando…
Advances in cancer research. Volume one hundred and thirty /
Advances in Cancer Research provides invaluable information on the exciting and fast-moving field of cancer research. Here, once again, outstanding and original reviews are presented on a variety of topics.
| Clasificación: | Libro Electrónico |
|---|---|
| Otros Autores: | , |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
Cambridge, MA :
Academic Press is an imprint of Elsevier,
2016.
|
| Edición: | First edition. |
| Colección: | Advances in Cancer Research.
|
| Temas: | |
| Acceso en línea: | Texto completo |
Tabla de Contenidos:
- Front Cover; Advances in Cancer Research; Copyright; Contents; Contributors; Chapter One: The Evolving, Multifaceted Roles of Autophagy in Cancer; 1. Introduction; 2. Overview of Autophagy; 2.1. Molecular Machinery of Autophagosome Biogenesis; 2.1.1. Initiation of Autophagosome Biogenesis by the ULK Complex; 2.1.2. Nucleation of the Phagophore by the Class III PI3K Complex; 2.1.3. Elongation of the Phagophore by the mAtg12 and LC3 Conjugation Systems; 2.2. Fusion; 2.3. Regulation of Mammalian Autophagy; 2.3.1. Nutrient and Growth Factor Starvation; 2.3.2. Hypoxia; 2.3.3. Oxidative Stress.
- 2.3.4. Endoplasmic Reticulum Stress2.3.5. DNA Damage; 2.3.6. Ionizing Radiation; 2.3.7. Immune System Activation; 2.3.8. Tumor Suppressor p53; 2.3.9. Epigenetic Modifications and mRNA Silencing; 2.4. Selective Capture of Autophagic Cargo in Mammals; 3. Tumor-Suppressive Roles for Autophagy in Cancer; 3.1. Genetic Basis for the Involvement of Autophagy in Tumor Suppression; 3.2. Inhibition of p62-Mediated Signaling Pathways; 3.3. Activation of Oncogene-Induced Senescence; 3.4. Maintenance of Immune Surveillance and Avoidance of Inflammation.
- 3.5. Clearance of Defective Mitochondria and Maintenance of Genomic Integrity3.6. Autophagy-Inducing Agents in Cancer Therapy; 4. Tumor-Promoting Roles for Autophagy in Cancer; 4.1. Genetic Evidence for the Involvement of Autophagy in Tumor Promotion; 4.2. Autophagy Supports Metabolic Adaptation to Accommodate Increased Biosynthetic Needs; 4.3. Survival Programs, Therapeutic Resistance, and Tumor Dormancy; 4.4. Interaction with the Tumor Microenvironment; 4.5. Autophagy-Inhibiting Agents in Cancer Therapy; 5. New Intersections Between Autophagy and Secretion.
- 5.1. Evidence for Autophagy-Dependent Secretion5.2. Emerging Roles for Autophagy-Dependent Secretion in Cancer; 6. Concluding Remarks and Perspectives; Acknowledgments; References; Chapter Two: Inhibitors of DNA Methylation, Histone Deacetylation, and Histone Demethylation: APerfect Combination for Ca ... ; 1. Introduction; 2. DNMTs: The Enzymes Responsible for DNA Methylation; 3. DNA-Demethylating Agents; 4. Azacytidine in RNA Metabolism; 5. Histone Acetylation; 5.1. Histone Deacetylases; 5.1.1. Class IHDACs; 5.1.2. Class II HDACs; 5.1.3. Class IV HDAC; 6. Nuclear Repressive Complexes.
- 6.1. Nucleosome Remodeling and Deacetylase Complex: ALink Between DNA Methylation, Histone Deacetylation, and Nucleosome ... 6.2. NCoR and SMRT Corepressor Complex; 6.3. Corepressor of RE1-Silencing Transcription Factor (CoREST) Repressor Complex; 7. HDAC Inhibitors: General Mechanism of Zinc Chelators; 7.1. Mechanisms of HDAC-Induced Anticancer Effects; 7.2. Hydroxamic Acid-Based Inhibitors: Vorinostat and Panobinostat; 7.3. Benzamide-Based HDAC Inhibitor: Entinostat; 7.4. Cyclic Tetrapeptide-Based Inhibitor: Romidepsin.